基于网络药理学探讨柴胡疏肝散治疗慢性前列腺炎的作用机制

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (2846 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the mechanism of Chaihu Shugan Powder in the treatment of chronic prostatitis based on network pharmacology. Methods According to the drug-likeness and oral bioavailability, the predictive targets of effective active ingredients of Chaihu Shugan Powder in the treatment of chronic prostatitis were screened through the pharmacology database analysis platform of traditional Chinese medicine system and GeneCards. The network graph of active component of Chaihu Shugan Powder-target of chronic prostatitis was drawn by Cytoscape 3.7.2. The network analysis of target interaction was made by STRING database. Finally, the target, signal pathway and biological process were analyzed in the biological information annotation database. Results A total of 129 active components were screened out, among which, the number of Citri Reticulatae Pericarpium, Bupleuri Radix, Chuanxiong Rhizoma, Cyperi Rhizoma, Aurantii Fructus, Paeoniae Radix Alba, Glycyrrhizae Radix Et Rhizoma was 5, 14, 6, 17, 5, 11, 71 respectively. A total of 1121 targets of active ingredients were obtained, including IL-6, IL-2, SRC, EGFR, IGF1R, and so on. KEGG pathway enrichment analysis showed that chemokine signaling pathway, MAPK signaling pathway, T cell signaling pathway and others were mainly involved. Conclusion This study reveals the potential target and KEGG signaling pathway of Chaihu Shugan Powder in the treatment of chronic prostatitis, which can provide new ideas for the mechanism of its intervention in chronic prostatitis.

Key words： Chaihu Shugan Powder Chronic prostatitis Network pharmacology Target Signal pathway

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Xiaoyun1 BA Yuanming2

Cite this article:

ZHU Xiaoyun1 BA Yuanming2. Exploration on the mechanism of Chaihu Shugan Powder in the treatment of chronic prostatitis based on network pharmacology[J]. 中国医药导报, 2021, 18(9): 30-34,47.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I9/30

[1] Paterson C，Kennedy C. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome [J]. Res Nurs Health，2020，43（5）：548-549.
[2] Schaeffer AJ，Datta NS，Fowler JE Jr，et al. Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome（CP/CPPS）[J]. Urology，2002，60（6 Suppl）：1-4.
[3] 张恩祈.针刺缓解慢性前列腺炎/慢性盆底疼痛综合征（湿热蕴结型）症状疗效观察[D].合肥：安徽中医药大学，2019.
[4] 黄天骄，郑入文.关于慢性前列腺炎中医病名的两点商榷[J].中医学报，2020，35（5）：980-982.
[5] 杨花平.正确选择治疗慢性前列腺炎的药物探讨[J].中国误诊学杂志，2007，7（26）：6252-6253.
[6] 张敏建，邓庶民，郭军，等.慢性前列腺炎中西医结合诊疗指南（试行版）[J].中国中西医结合杂志，2007，27（11）：1052-1056.
[7] 张宏武，邹忠梅.柴胡疏肝散的临床应用及现代研究进展[J].时珍国医国药，2007，18（5）：1234-1236.
[8] Holt JD，Garrett WA，McCurry TK，et al. Common Questions About Chronic Prostatitis [J]. Am Fam Physician，2016，93（4）：290-296.
[9] Yan Z，Huang C，Huang G，et al. Jiedu Huoxue decoction improves inflammation in rat type Ⅲ prostatitis：The importance of the NF-κB signalling pathway [J]. Andrologia，2019，51（5）：e13245.
[10] 董培良，李慧，韩华.中药网络药理学的应用与思考[J].中国实验方剂学杂志，2020，26（17）：204-211.
[11] 周圆，彭林发，梁啦迪，等.前列康片在治疗Ⅲ型慢性前列腺炎患者中的效果及对血清炎症因子的影响[J].四川医学，2018，39（11）：1261-1264.
[12] 贺元才，王荣江.盐酸坦索罗辛对慢性前列腺炎患者血清炎症因子的影响[J].中国性科学，2017，26（2）：5-7.
[13] 甘进，王晓荣.IL-6和IL-8在慢性前列腺炎患者精液中的表达及临床意义[J].江西医药，2020，55（8）：1050-1051，1060.
[14] Drannik GN，Gorpynchenko II，Nurimanov KR，et al. Relationships Among Depression and Levels of Cytokines and Testosterone in Patients with Chronic Abacterial Prostatitis [J]. J Allergy Clin Immunol，2017，139（2）：AB209.
[15] Vergadi E，Ieronymaki E，Lyroni K，et al. Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization [J]. J Immunol，2017，198（3）：1006-1014.
[16] 刘文艳，鞠志花，刘顺德，等.Src基因研究进展[J].家畜生态学报，2010，31（2）：87-90.
[17] 马莉，艾庆燕.VEGF、KDR在精索静脉曲张大鼠睾丸中的表达意义[J].生命科学仪器，2016，14（3）：50-52，57.
[18] 杨宗纯.基于NEI网络和转录组学技术探查柴胡疏肝散与肝郁证关联的生物学基础[D].北京：北京中医药大学，2019.
[19] Gaud G，Lesourne R，Love PE. Regulatory mechanisms in T cell receptor signaling [J]. Nat Rev Immunol，2018，18（8）：485-497.
[20] Sultanova A，Cistjakovs M，Sokolovska L，et al. HHV-6 Infection and Chemokine RANTES Signaling Pathway Disturbance in Patients with Autoimmune Thyroiditis [J]. Viruses，2020，12（6）：689.
[21] Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits [J]. Biochim Biophys Acta，2005，1754（1/2）：253-262.
[22] 秦素，江永浩，付招伦，等.UPOINT临床表型分类法在慢性前列腺炎/慢性盆底疼痛综合征诊治中应用研究[J].中国男科学杂志，2016，30（2）：8-12.
[23] Ji RR，Nackley A，Huh Y，et al. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain [J]. Anesthesiology，2018，129（2）：343-366.
[24] Wong L，Done JD，Schaeffer AJ，et al. Experimental autoimmune prostatitis induces microglial activation in the spinal cord [J]. Prostate，2015，75（1）：50-59.
[25] 张敏建，宾彬，商学军，等.慢性前列腺炎中西医结合诊疗专家共识[J].中国中西医结合杂志，2015，35（8）：933-941.
[26] Pace TW，Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression [J]. Ann N Y Acad Sci，2009，1179：86-105.
[27] 卢玲，庄胜，陈炜，等.柴胡疏肝散辅助治疗重度抑郁症的网络药理学研究[J].中国药房，2020，31（13）：1569-1574.